SFDA Aims To Boost Healthcare Safety With Medical Associations' Support

Dr. Hisham S. Aljadhey, the Chief Executive Officer of the Saudi Food and Drug Authority (SFDA), inaugurated a workshop at the SFDA headquarters in Riyadh. The event, held on Monday, aimed to bolster partnerships with specialized medical associations. Presidents and members of these associations attended the workshop.

In his opening remarks, Dr. Aljadhey highlighted the importance of this meeting in enhancing cooperation between the SFDA and medical associations. He stressed the need for collaboration with healthcare practitioners and establishing effective communication channels with these associations.

Dr. Aljadhey emphasized that healthcare practitioners and medical associations play a vital role in supporting the 'Fourth Strategy' of the SFDA, which focuses on product safety. This strategy aims to build trust among healthcare practitioners and improve communication and awareness among both the public and medical professionals.

The workshop included an overview of the pharmaceutical sector in Saudi Arabia, showcasing several successful collaboration initiatives with medical associations. The importance of continuing such meetings was underscored during the discussions.

Key topics covered included creating educational programs on drug safety and effectiveness, disseminating information about medication risks, conducting research studies, engaging with SFDA-published scientific data, and encouraging the reporting of drug side effects.

Ongoing Efforts for Collaboration

This workshop is part of SFDA’s ongoing efforts to strengthen its relationship with medical associations. The aim is to gather input from specialists and identify areas of collaboration to achieve shared goals.

Dr. Aljadhey noted that collaborating with healthcare practitioners is crucial for building effective communication channels with these associations. He reiterated that such partnerships are essential for supporting SFDA's strategies focused on product safety.

The workshop also highlighted several successful initiatives that have resulted from collaborations between SFDA and medical associations. These initiatives have played a significant role in advancing the pharmaceutical sector in Saudi Arabia.

The event concluded by emphasizing the need for continuous engagement between SFDA and medical associations to ensure ongoing improvement in drug safety education, risk dissemination, research studies, scientific data engagement, and adverse effect reporting.

With inputs from SPA